Fuse Advisory has been delighted to assist TBG Diagnostics Limited (TBG) (ASX: TDL) on its successful relisting on the ASX following its successful $21 million acquisition of in-vitro diagnostic company TBG Inc. TBG was readmitted to the ASX on 3 February 2016 following a successfully $12.7m capital raising whose proceeds will be used to fund the company’s strategic growth plans.
On relisting, TBG core focus will be as an in-vitro diagnostics (IVD) company involved in work such as:
- developing Nucleic Acid Test (NAT) products;
- developing human leukocyte antigen (HLA) typing reagents based on NAT technologies;
- developing automation systems for NAT operations; and
- development, manufacture and marketing of IVD related NAT kits and services
The Fuse team advising TBG was led by its Principal Chris Burrell. Fuse acted as lead transaction lawyers and as Australian legal counsel on the capital raising and on the merger agreement which effected the acquisition of TBG Inc, Fuse also acted as legal counsel in connection with all aspects of TBG’s readmission to the ASX including preparation of the prospectus for the capital raise, the notice of meeting approving the acquisition and the capital raising.
Other advisers included independent experts William Buck and investigating accounts BDO.